Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-01-11
2005-01-11
Barts, Samuel (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
06841543
ABSTRACT:
Methods for modulating immune responses are provided. The methods involve contacting an immune cell with an agent that modulates interaction of a compound comprising a Lewis antigen with the immune cell such that production by the immune cell of at least one cytokine that regulates development of a T helper type 1 or T helper type 2 response is modulated. In one embodiment, the agent is a stimulatory form of a compound comprising a Lewis antigen, such as a Lewisy, Lewisxor Lewisaoligosaccharide, or a derivative thereof. In another embodiment, the agent is an inhibitory form of a compound comprising a Lewis antigen, such as a Lewisy, Lewisxor Lewisaoligosaccharide, or a derivative thereof. In various embodiments, the immune cell is a human immune cell, a macrophage or a T cell. Pharmaceutical compositions for modulating immune responses are also provided.
REFERENCES:
patent: 5210078 (1993-05-01), Toyokuni et al.
patent: 5352670 (1994-10-01), Venot et al.
patent: 5426178 (1995-06-01), Laine et al.
patent: 5559103 (1996-09-01), Gaeta et al.
patent: 5580858 (1996-12-01), Ippolito et al.
patent: 5965544 (1999-10-01), Renkonen et al.
patent: WO 9204048 (1992-03-01), None
patent: WO 9222565 (1992-12-01), None
patent: WO 9321948 (1993-11-01), None
patent: WO 9411498 (1994-05-01), None
patent: WO 9527500 (1995-10-01), None
Williams et al. J. Inf. Dis. 170:946-54 1994.*
Moore et al. Annu. Rev. Immunol. 11:165-90 1993.*
Velupillai and Harn Human Immunol. 61:225-232 2000.*
Tyrell et al. PNAS 88:10372 1991.*
Fenderson, Bruce A. et al. (1984) “A Multivalent Lacto-N-Fucopentaose III-Lysyllysine Conjugate Decompacts Preimplantation Mouse Embryos, While The Free Oligosaccharide Is Ineffective” J. Exp. Med., vol. 60, pp. 1591-1596.
Berg, E. L. et al., “Comparison of L-Slectin and E-Selectin Ligand Specificities: The L-Selectin Can Bind the E-Selectin Ligands Sialyl Lexand Sialyl Lea”,Biochemical and Biophysical Research Communications, vol. 184, No. 2, pp. 1048-1055 (1992).
Fortune, F. et al., “The Expression of Carbohydrate Antigens in Activated T Cells and in Autoimmune Diseases”,Scand J. Immunol., vol. 40, pp. 636-642 (1994).
Foxall, C. et al., “The Three Members of the Selectin Receptor Family Recognize a Common Carbohydrate Epitope, the Sialyl LewisxOligosaccharide”,Journal of Cell Biology, vol. 17, No. 4, pp. 895-902 (1992).
Hakomori, S.-I. “LexRelated Structures as Adhesion Molecules”,Histochemical Journal, vol. 24, pp. 771-776 (1992).
Halpern, M.T. et al., “Modulation of a Human Immunosuppressive Lymphokine by Monosaccarides”,Cellular Immunology, vol. 136, pp. 29-40 (1991).
Harn, D. A. et al., “Regulation of CD4+T-Cell Subsets in Schistosomiasis: Specific Oligosaccharides Stimulate B220+Spleen Cells to Proliferate and Secrete IL-10 and Also are Responsible for Recruitment of Peritoneal B-1 Cells”, Abstract for11th Annual Meharry Medical College Symposium, (Apr. 4, 1994).
Harn, D. A. et al., “LNFPIII Elevates B-1 Cells in the Peritoneal Cavity and May Indirectly Regulate CD4+T-Cells”,The FASEB Journal, vol. 8, No. 4, Abstract 2725 (1994).
Kageshita, T. et al., “Association Between Sialyl LewisaExpression and Tumor Progression in Melanoma”,Cancer Research, vol. 55, No. 8, p. 1748-1751 (1995).
Kitamura, K. et al., “Specificity Analysis of Blood Group Lewis-y (Ley) Antibodies Generated Against Synthetic and Natural LeyDeterminants”,Proc. Natl. Acad. Sci. USA, vol. 91, pp. 12957-12961 (1994).
Ko, A. I. et al., “ASchistosoma mansoniEpitope Recognized by a Protective Monoclonal Antibody is Identical to the Stage-Specific Embryonic Antigen 1”,Proc. Natl. Acad. Sci., USA, vol. 87, pp. 4159-4163 (1990).
Kokai, M. et al., “Elevated LeyAntigen Expression on T-Lymphocytes in Schizophrenic Patients”,Eur Arch Psychiatry Clin Neurosci,vol. 243, pp. 82-86 (1993).
Kuchroo, V. K. et al., “B7-1 and B7-2 Costimulatory Molecules Activate Differentially the Th1/Th2 Developmental Pathways: Application to Autoimmue Disease Therapy”,Cell,vol. 80, pp. 707-718 (1995).
Martensson, S. et al., “Sialyl-Lewisxand Related Carbohydrate Antigens in the Prostate”,Hum Pathol., vol. 26, pp. 735-739 (1995).
Muguruma, M. et al., “Hepatic Neoexpression and Increased Plasma Levels of Lewis Y, a Carbohydrate Antigen, in Chronic Inflammatory Liver Diseases”,Am. J. Clin Pathol, vol. 102, pp. 176-181 (1994).
Ohta, S. et al., “Tumor-Associated Glycoantigen, Sialyl Lewisaas a Target for Bispecific Antibody-Directed Adoptive Tumor Immunotherapy”,Immunology Letters, vol. 44, pp. 35-40 (1995).
Okada, Y. et al., “Neoexpression of Sialyl Oligomeric Lewis y by Kupffer Cells in Chronic Hepatitis”,Lancet,vol. 335, pp. 1302-1306 (1990).
Paavonen, T., et al., “Selective Expression of Sialyl-Lewis X and Lewis A Epitopes, Putative Ligands for L-Selectin, on Peripheral Lymph-Node High Endothelial Venules”,American Journal of Pathology, vol. 141, No. 6, pp. 1259-1264 (1992).
Ryan, C. A., “Oligosaccharide Signals: From Plant Defense to Parasite Offense”,Proc. Natl. Acad. Sci. USA, vol. 91, pp. 1-2 (1994).
Van Dam, G. J. et al., “The Immunologically Reactive O-Linked Polysaccharide Chains Derived from Circulating cathodic Antigen Isolated from the Human Blood FlukeSchistosoma mansonihave Lewis x as Repeating Unit”,Eur. J. Biochem., vol. 225, pp. 467-482 (1994).
Velupillai, P. et al., “Oligosaccharide Interactions with Mononuclear Cells from Mice Infected withSchistosoma mansonior Trypanosoma Cruzi May Lead to CD4+ T Cell Subset Regulation”, Abstract for Am. Soc. of Tropical Medicine and Hygiene Meeting (Nov. 1993).
Velupillai, P. et al., “Recombinant Murine IL-12 Inhibits Ligand-Specific Recruitment of Peritoneal B220+, CD5+(B-1) Cells”, Abstract for Clinical Immunology Meeting (Apr. 1994).
Velupillai, P. et al., “Oligosaccharide-Specific Induction of Interleukin 10 Production by B220+Cells from Schistosome-Infected Mice: A Mechanism for Regulation of CD4+T-Cell Subsets”,Proc. Natl. Acad. Sci. USA, vol. 91, pp. 18-22 (1994).
Velupillai, P., et al., “Interleukin-12 and -10 and Gamma Interferon Regulate Polyclonal and Ligand-Specific Expansion of Murine B-1 Cells”,Infection and Immunity, vol. 64, No. 11, pp. 4557-4560 (1996).
Harn Donald A.
Velupillai Palanivel
Barts Samuel
DeConti, Jr. Esq. Giulio A.
Kanik Cynthia L.
Maier Leigh C.
President and Fellows of Harvard College
LandOfFree
Methods of inhibiting production of T helper type 2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting production of T helper type 2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting production of T helper type 2... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3371235